Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AGBL2 | Q5U5Z8 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.38 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.36 |
| ▸ | GABRE | P78334 | 2/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23374468 | 0.81 | HTT (0.34) | LMNASMN1; SMN2CA2PDE4A | |
| SCHEMBL26046044 | 0.81 | PDE4A (0.34) | LMNASMN1; SMN2KMT2APDE4A | |
| SCHEMBL1808064 | 0.76 | PDE4A (0.33) | LMNASMN1; SMN2PDE4A | |
| SCHEMBL230258 | 0.76 | PDE4A (0.31) | POLBPDE4A | |
| SCHEMBL28007568 | 0.76 | GABRR1 (0.42) | GABRR1LMNAAGBL2AKR1B1GABRP | |
| SCHEMBL27598251 | 0.74 | GABRR1 (0.41) | GABRR1LMNASMN1; SMN2AGBL2AKR1B1 | |
| SCHEMBL27887048 | 0.74 | GABRR1 (0.50) | GABRR1SMN1; SMN2AGBL2AKR1B1GABRP | |
| SCHEMBL4860930 | 0.74 | GABRA5 (0.44) | GABRR1AGBL2AKR1B1GABRPGABRD | |
| Acetic Acid SCHEMBL18956025 | 0.74 | SMN1; SMN2 (0.36) | LMNASMN1; SMN2KDM4EPOLB | |
| SCHEMBL30546480 | 0.74 | AKR1B1 (0.52) | LMNASMN1; SMN2AKR1B1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531648-B | Herbicidal compounds | 先正达参股股份有限公司 | 2021-07-13 | — | — | CN | disclosed |
| US-10385063-B2 | Herbicidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2019-08-20 | — | — | US | disclosed |
| US-10385063-B2 | Herbicidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2019-08-20 | — | — | US | disclosed |
| EP-3288924-B1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2019-04-03 | — | — | EP | disclosed |
| EP-3288924-B1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2019-04-03 | — | — | EP | disclosed |
| US-20180111948-A1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-04-26 | — | — | US | disclosed |
| US-20180111948-A1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-04-26 | — | — | US | disclosed |
| EP-3288924-A1 | HERBICIDAL COMPOUNDS | Syngenta Participations AG (CH) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016174073-A1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016174073-A1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-11-03 | — | — | WO | disclosed |
| US-20130303370-A1 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2013-11-14 | — | — | US | disclosed |
| US-20130303370-A1 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2013-11-14 | — | — | US | disclosed |
| CN-103347865-A | Herbicidal compounds | SYNGENTA LTD | 2013-10-09 | — | — | CN | disclosed |
| EP-2638019-A1 | HERBICIDAL COMPOUNDS | Syngenta Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-8258136-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-04 | — | — | US | disclosed |
| WO-2012062531-A1 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062531-A1 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
| US-20090275589-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-7456192-B2 | 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2008-11-25 | — | — | US | disclosed |
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | AOC3, MAOB, AOC1 | GABRR1 778/4885LMNA 3214/4885SMN1; SMN2 2170/4885 |
| US-10385063-B2 | Herbicidal compounds | DDT, DAO, HPD | GABRR1 3114/4885LMNA 2967/4885SMN1; SMN2 4553/4885 |
| US-20180111948-A1 | HERBICIDAL COMPOUNDS | DDT, DAO, HPD | GABRR1 3097/4885LMNA 2984/4885SMN1; SMN2 4544/4885 |
| US-20090275589-A1 | Pyridazine Compound and Use Thereof | PLPBP, PNPO, PDXK | GABRR1 4655/4885LMNA 2869/4885SMN1; SMN2 2463/4885 |
| US-20130303370-A1 | HERBICIDAL COMPOUNDS | DDT, CYP4X1, CYP1B1 | GABRR1 2048/4885LMNA 4600/4885SMN1; SMN2 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.